ANTI-CD98hc ANTIBODY

Abstract

Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

What is claimed is: 
     
         1 . A monoclonal anti-CD98hc antibody comprising
 a heavy chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 4, and   a light chain variable region comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 9,   wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, and the amino acid sequence of SEQ ID NO: 3; and   wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8.   
     
     
         2 . The antibody according to  claim 1 , comprising
 a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4, and   a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.   
     
     
         3 . The antibody according to  claim 1 , which is an Fv, scFv, diabody, triabody, or tetrabody. 
     
     
         4 . The antibody according to  claim 1 , which is a chimeric antibody or a humanized antibody. 
     
     
         5 . The antibody according to  claim 1 , which is an Fab, F(ab)′, minibody, or scFv-Fc. 
     
     
         6 . The antibody according to  claim 1 , having a substance having cytotoxic activity, an enzyme, a tag, or an immunomodulator bound thereto. 
     
     
         7 . A pharmaceutical composition comprising the antibody according to  claim 1  and a pharmaceutically acceptable excipient.